OTC erythromycin
This article was originally published in The Tan Sheet
Executive Summary
FDA's Dermatologic Drugs and Anti-Infective Drugs Advisory Committees will discuss the potential for development of antibiotic resistance with OTC use of topical erythromycin in the treatment of acne at a Sept. 23 joint session at FDA headquarters in Rockville, Md